Last reviewed · How we verify
NCT03356678
Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma
trial testing Pralatrexate in Relapsed or Refractory Peripheral T-cell Lymphoma in 33 participants. Completed in 30 June 2017.
30 June 2017
Quick facts
| Lead sponsor | Samsung Medical Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 33 |
| Start date | 23 September 2016 |
| Primary completion | 30 June 2017 |
| Estimated completion | 30 June 2017 |
| Sites | 2 locations across South Korea |
Drugs / interventions tested
- Pralatrexate — full drug profile →
Conditions studied
- Relapsed or Refractory Peripheral T-cell Lymphoma — all drugs for Relapsed or Refractory Peripheral T-cell Lymphoma →
Sponsor
Samsung Medical Center
Who can join
18 and older, any sex, with Relapsed or Refractory Peripheral T-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A non-interventional, multicenter, multinational retrospective analysis using electronic case report forms completed by the investigators based on information from patient medical records
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03356678
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pralatrexate
Trials testing the same drug.
- NCT07225985 — Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Re · Phase 1, PHASE2 · not yet recruiting
- NCT07234162 — A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) · Phase 3 · recruiting
- NCT03240211 — Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL · Phase 1 · active not recruiting
- NCT04747236 — Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL · Phase 2 · recruiting
- NCT03598998 — Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas · Phase 1, PHASE2 · active not recruiting
Other Samsung Medical Center trials
Trials by the same sponsor.
- NCT07482865 — Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support · NA · not yet recruiting
- NCT07467213 — Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute M · Phase 4 · not yet recruiting
- NCT07530913 — Effectiveness Analysis of a Rehabilitation Exercise Platform for Living Donor Liver Transplantation Patients · NA · enrolling by invitation
- NCT07500701 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Pro · Phase 3 · recruiting
- NCT07409441 — Korea Acute Myocardial Infarction Registry · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03356678 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Samsung Medical Center
- Last refreshed: 29 November 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03356678.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing